NORML Says DEA’s Newly Proposed Bulk Cultivation Rules Are “Unduly…

  • NORML Says DEA’s Newly Proposed Bulk Cultivation Rules Are Unduly Onerous, Expensive, and Impractical
  • For the second time in four years, the US Drug Enforcement Administration is proposing regulatory changes to procedures governing the federally licensed manufacture of cannabis for clinical research purposes.
  • In a Notice of Proposed Rulemaking , published this week in the Federal Register , the agency acknowledges its longstanding failure to act upon the 35 bulk cultivation applications before it.
  • Under the proposed changes, the agency would purchase and warehouse all of the cannabis produced by federally licensed manufacturers.

Read full article: blog.norml.org